Glucagon-Like Peptide-1 Strengthens the Barrier Integrity in Primary Cultures of Rat Brain Endothelial Cells Under Basal and Hyperglycemia Conditions

Journal of Molecular Neuroscience

Volumn 59, Issue 2, 2016, Pages 211-219

  Fukuda, Shuji ^a   Nakagawa, Shinsuke ^a   Tatsumi, Rie ^a   Morofuji, Yoichi ^a   Takeshita, Tomonori ^a   Hayashi, Kentaro ^a   Tanaka, Kunihiko ^b   Matsuo, Takayuki ^a   Niwa, Masami ^c  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c PharmaCo Cell Company Ltd   (Japan)

Author keywords

Blood brain barrier; cAMP PKA signaling; Glucagon like peptide 1; Hyperglycemia; Tight junctions

Indexed keywords

CLAUDIN 5; CYCLIC AMP; FLUORESCEIN SODIUM; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; OCCLUDIN; REACTIVE OXYGEN METABOLITE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; ISOQUINOLINE DERIVATIVE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ANIMAL CELL; ARTICLE; BASAL BODY TEMPERATURE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN CELL CULTURE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRIC RESISTANCE; HYPERGLYCEMIA; IN VITRO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CAPILLARY PERMEABILITY; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; METABOLISM;

ANIMALS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELLS, CULTURED; CLAUDIN-5; ENDOTHELIAL CELLS; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; ISOQUINOLINES; OCCLUDIN; PROTEIN KINASE INHIBITORS; RATS; REACTIVE OXYGEN SPECIES; SULFONAMIDES;

EID: 84949762182     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-015-0696-1     Document Type: Article

References (43)

1. Abbott NJ (2002) Astrocyte-endothelial interactions and blood–brain barrier permeability. J Anat 200:629–638
2. Abbott NJ (2005) Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol 25:5–23
3. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood–brain barrier. Neurobiol Dis 37:13–25
4. Balteau M, Van Steenbergen A, Timmermans AD et al (2014) AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am J Physiol Heart Circ Physiol 307:H1120–H1133
5. Beese M, Wyss K, Haubitz M, Kirsch T (2010) Effect of cAMP derivates on assembly and maintenance of tight junctions in human umbilical vein endothelial cells. BMC Cell Biol 11:68. doi:10.1186/1471-2121-11-68
6. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC (1983) Exon duplication and divergence in the human preproglucagon gene. Nature 304:368–371
7. Boueiz A, Hassoun PM (2009) Regulation of endothelial barrier function by reactive oxygen and nitrogen species. Microvasc Res 77:26–34
8. Briyal S, Gulati K, Gulati A (2012) Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res 1427:23–34
9. Darsalia V, Ortsäter H, Olverling A et al (2013) The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes 62:1289–1296
10. Deli MA, Ábrahám CS, Kataoka Y, Niwa M (2005) Permeability studies on in vitro blood–brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 25:59–127
11. Dodge-Kafka KL, Soughayer J, Pare GC et al (2005) The protein kinase a anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437:574–578
12. Donnelly D (2012) The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol 166:27–41
13. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705
14. During MJ, Cao L, Zuzga DS et al (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9:1173–1179
15. Erdogdu Ö, Eriksson L, Nyström T, Sjöholm Å, Zhang Q (2012) Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells. Biochem Biophys Res Commun 419:790–795
16. Ergul A, Li W, Elgebaly MM, Bruno A, Fagan SC (2009) Hyperglycemia, diabetes and stroke: focus on the cerebrovasculature. Vasc Pharmacol 51:44–49
17. Furuse M, Tsukita S (2006) Claudins in occluding junctions of humans and flies. Trends Cell Biol 16:181–188
18. Ishizaki T, Chiba H, Kojima T et al (2003) Cyclic AMP induces phosphorylation of claudin-5 immunoprecipitates and expression of claudin-5 gene in blood–brain-barrier endothelial cells via protein kinase a-dependent and -independent pathways. Exp Cell Res 290:275–288
19. Lee CH, Yan B, Yoo KY et al (2011) Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res 89:1103–1113
20. Li Z, Liu YH, Xue YX, Xie H, Liu LB (2011) Role of ATP synthase alpha subunit in low-dose endothelial monocyte-activating polypeptide-II-induced opening of the blood-tumor barrier. J Neurol Sci 300:52–58
21. Li AQ, Zhao L, Zhou TF, Zhang MQ, Qin XM (2015) Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation. Am J Physiol Cell Physiol 308:C164–C175
22. Lovshin JA, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262–269
23. Maurice DH (2011) Subcellular signaling in the endothelium: cyclic nucleotides take their place. Curr Opin Pharmacol 11:656–664
24. McClean PL, Hölscher C (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology 76:57–67
25. McClean PL, Parthsarathy V, Faivre E, Hölscher C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci 31:6587–6594
26. Miyoshi J, Takai Y (2005) Molecular perspective on tight-junction assembly and epithelial polarity. Adv Drug Deliv Rev 57:815–855
27. Nakagawa S, Deli MA, Nakao S et al (2007) Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol 27:687–694
28. Nakagawa S, Deli MA, Kawaguchi H et al (2009) A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 54:253–263
29. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH (2010) Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 30:1407–1414
30. Perriere N, Demeuse P, Garcia E et al (2005) Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood–brain barrier-specific properties. J Neurochem 93:279–289
31. Perry T, Lahiri DK, Sambamurti K et al (2003) Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (abeta) levels and protects Hippocampal neurons from death induced by abeta and iron. J Neurosci Res 72:603–612
32. Pun PB, Lu J, Moochhala S (2009) Involvement of ROS in BBB dysfunction. Free Radic Res 43:348–364
33. Sato K, Kameda M, Yasuhara T et al (2013) Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci 14:21513–21524
34. Shao B, Bayraktutan U (2013) Hyperglycaemia promotes cerebral barrier dysfunction through activation of protein kinase C-beta. Diabetes Obes Metab 15:993–999
35. Sjöholm A (2009) Impact of glucagon-like peptide-1 on endothelial function. Diabetes Obes Metab Suppl 3:19–25
36. Spindler V, Schlegel N, Waschke J (2010) Role of GTPases in control of microvascular permeability. Cardiovasc Res 87:243–253
37. Tureyen K, Bowen K, Liang J, Dempsey RJ, Vemuganti R (2011) Exacerbated brain damage, edema and inflammation in type-2 diabetic mice subjected to focal ischemia. J Neurochem 116:499–507
38. Van Itallie CM, Anderson JM (2006) Claudins and epithelial paracellular transport. Annu Rev Physiol 68:403–429
39. Vannucci SJ, Willing LB, Goto S et al (2001) Experimental stroke in the female diabetic, db/db, mouse. J Cereb Blood Flow Metab 21:52–60
40. Wohlfart P, Linz W, Hübschle T et al (2013) Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Transl Med 11:84. doi:10.1186/1479-5876-11-84
41. Yan J, Zhang Z, Shi H (2012) HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells. Cell Mol Life Sci 69:115–128
42. Yang D, Nakajo Y, Iihara K, Kataoka H, Yanamoto H (2013) Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res 1517:104–113
43. Zlokovic BV (2008) The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201